Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
NYSE COMPOSITE INDX
Gold
Crude Oil
CYTRX
(NQ:
CYTR
)
2.120
USD
-0.020 (-0.93%)
Streaming Delayed Price
/ Updated:
1:13 PM EDT, Jun 19, 2013
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Options
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Podcasts
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Intraday
1 Week
1 Month
3 Month
1 Year
Compare to:
None
S&P 500
Nasdaq
NYSE
AMEX
Russell 2000
Basic Materials
Conglomerates
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities
Volume
6,786
Open
2.140
Bid (Size)
2.120 (10000)
Ask (Size)
2.130 (300)
Prev. Close
2.140
Today's Range
2.100 - 2.172
52wk Range
1.590 - 5.500
Shares Outstanding
30,517,370
Dividend Yield
N/A
Top News
More News
UPDATE: Aegis Capital Lowers PT on CytRx on Continued Aldoxorubicin Trial Results
Today 10:30 EDT
In a report published Wednesday, Aegis Capital analyst Raghuram Selvaraju reiterated a Buy rating on CytRx (NASDAQ: CYTR ), but lowered the price target from $8.00 to $7.00. In the report, Aegis...
Read More
category
CYTR
,
Benzinga
,
Raghuram Selvaraju
, and 4 more.
from
Latest Articles from Benzinga.com
New Biotech Names with Excellent Prospects: Michael Aitkenhead
June 13, 2013
New Biotech Names with Excellent Prospects: Michael Aitkenhead Source: George S. Mack of The Life Sciences Report (6/13/13) http://www.thelifesciencesreport.com/pub/na/15361 In a marketplace as diverse...
Read More
category
CYTR
,
OVSC
,
NVS
, and 5 more.
from
Bio-Wire.Com
More News
Read More
CytRx Announces the Presentation of Favorable Results from Novel Combination of Aldoxorubicin and Doxorubicin in a Phase 1b Clinical Trial at ASCO Conference
June 03, 2013
from
Business Wire News Releases
CytRx to Present at the Marcum MicroCap Conference
May 23, 2013
from
Business Wire News Releases
CytRx Announces Initial Results from Pharmacokinetics Clinical Trial with Aldoxorubicin in Solid Tumors
May 21, 2013
from
Business Wire News Releases
CytRx Issues Letter to Stockholders Providing Business Update
May 20, 2013
from
Business Wire News Releases
CytRx Corp (CYTR) Posts Q1 Loss of 23c/Share
May 09, 2013
from
StreetInsider.com News Articles
CytRx Reports 2013 First Quarter Financial Results
May 09, 2013
from
Business Wire News Releases
Free Research Reports on CYTR, ICUI, MYGN and WBMD Issued by the Bedford Report
May 09, 2013
from
Marketwired News Releases
CytRx Provides Update on Clinical Programs
May 08, 2013
from
Business Wire News Releases
Stock Market XML and JSON Data API
provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays.
Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Press Release Service
provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates
Bots go here